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Abstract  
Cancer cachexia is a type of cancer metabolic syndrome characterized by wasting of energy storage tissue of the 
body such as loss of skeletal muscle or fat body mass. It is one of the most common forms of cachexia. 
Researchers have shown that around 50%–80% cancer patients are cachectic and about 22% cancer related 
deaths are due to cachexia. Recent evidences confirm that skeletal muscle loss is induced by different mediator 
based mechanisms such as cytokines, tumor-derived factors, TNF-alpha receptors, androgen receptors, negative 
modulator of growth factors, and ubiquitin-proteasome pathways. These mediators interact with their unique 
receptors on skeletal muscles and activate nuclear factor-kappa-B (NF-κB) which is a transcription factor 
essential for atrophy based muscle protein degradation. Inhibition of NF-κB ameliorates cancer-induced muscle 
loss are suggestive of a new set of drug targets for clinical intervention in cancer cachexia. Here we summarize 
the recent advances concerning involvement of NF-κB in loss of skeletal muscle mass in cancer cachexia and its 
therapeutic targets. Future experimental efforts may focus on discovering of new drugs that act as potential 
therapeutic targets in cancer cachexia against the myriad of signaling pathways to precisely understand the 
mechanisms of loss of skeletal muscle mass and adipose tissue which could demonstrates significant 
improvement in treatment outcome, functional status and quality of life of the patients.  
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Introduction 
Cachexia can occur under a variety of disease 
states such as AIDS, heart failure, sepsis, 
diabetes and cancer. Cancer cachexia is a 
multi-factorial syndrome defined by an 
ongoing wasting of skeletal muscle mass (with 
or without loss of fat moss) that cannot be 
completely reversed by nutritional treatments 
and leads to progressive functional impairment 
[1].Thus, the loss of skeletal muscle mass is 
the main characteristic feature of cancer 
cachexia where intracellular protein 
degradation and several extracellular 
alterations including the breakdown of muscle 
basement membrane and intramuscular 
connective tissues, have been attributed. 
Published literature indicates that out of total 
cancer patients, 50%–80% patients become 
cachectic and about 20-30% deaths are due to 
cancer cachexia [2]. Cancer patients suffering 
from cachexia have lower survival rate due to 
loss of skeletal muscles, which in turn affects 
the muscle strength, mobility, fatigue, and 
quality of life [1-5]. 
Accumulating evidences suggest that 
various stimuli trigger muscle wasting either 
by reducing protein synthesis, or enhancing 
the degradation of skeletal muscle protein or 
sometimes by both [3, 6-8]. Although the 
triggering mechanisms for each type of muscle 
wasting may be unique, there are common sets 
of transcriptional and biochemical changes 
augmenting the cell capacity for protein 
breakdown in skeletal muscle loss. Earlier 
studies have suggested different mediator 
based mechanisms that cause loss of 
skeletal muscle mass such as; cytokines, 
tumor-derived factors, TNF-alpha receptors, 
androgen receptors, ubiquitin-proteasome 
pathway, negative modulators 
of muscle growth, and intracellular signaling 
pathways
 
[3,4,7,8,10-11]. Earlier published 
reports have established that increased 
expression of muscle specific 
ubiquitin-conjugating enzymes (E3 ligases i.e. 
MAFbx/ atrogin-1, MMP9, MuRF1, and 
E3II) play major role in degradation of a 
bulk of muscle proteins in various distinct 
conditions [3, 12-15]. Although 
etiopathogenesis of cachexia is poorly 
understood, several studies suggested that 
expression of various genes such as MyoD, 
cyclin [12, 16-19], ubiquitin-conjugating
 
E2 
enzyme UbcH2/E220k [11,20], MuRF1 [6,21], 
MMP9 [22] and inflammatory cytokines [6,23]
  
are tightly controlled by coordinated action of
  
NF-kB signaling pathways. Moreover, some 
studies on cachexia indicate that increased 
proteolysis and apoptosis induction are 
mediated by NF-κB up-regulation [24-26].    
Recently significant progress has been made 
in understanding the signaling mechanisms 
linked to cachexia such as smads [27], 
AP-1[28], IFNγ [29], Foxo1 [30-31], and 
NF-κB [6, 31]. Among them, the activation of 
the nuclear factor-kappa B (NF-kB) signaling 
pathway has been reported to be essential for 
degradation of muscle protein in humans and 
rodents [6-9, 21]. In fact, several genetic and 
pharmacological studies in experimental 
animal models have shown that inhibition of 
NF-kB can prevent skeletal muscle loss in a 
wide variety of stimuli suggesting that NF-kB 
can serve as an important molecular target in 
future therapies [4,6,7,8,21-23]. Although the 
underlying mechanisms in skeletal muscle loss 
have been elucidated, but there is no 
comprehensive review discussing the NF-κB 
mediated therapeutic targets in skeletal muscle 
loss in cancer cachexia. In present review, we 
have summarized the recent advances in 
NF-κB mediated skeletal muscle loss  due to 
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cancer cachexia along with its therapeutic 
targets. 
NF-B signaling pathway 
NF-kB is a REL family of transcription factors, 
which regulates >150 genes that are involved 
in a variety of cellular processes depending on 
the cell types and upstream triggers such as: 
cytokines, immune cell receptors, 
antigen-presenting receptors, regulators of 
redox status, acute-phase response, apoptosis, 
disuse atrophy, host defense and cancer 
cachexia [4,8,10, 23].  
NF-κB consists of a family of 5 members: 
p105/p50, p100/p52, p65 (RelA), RelB, and 
c-Rel, all sharing the Rel homology domain 
which allows their dimerization and 
translocation to the nucleus in mammalian 
cells. Evidences from human and rodent 
studies suggest that p50-p65 heterodimer plays 
a major role in activation of NF-κB 
transcription factor in skeletal muscle cells 
[3,6,7,9]. Before activation, NF-κB dimers are 
retained in the cytoplasm by binding to 
specific inhibitors of NF-κB known as 
inhibitory kappa-B (IκB) proteins. Seven 
different IκB are found in mammalian cells 
including; IκBα, IκBβ, IκBε, IκBγ, BCL-3 and 
precursor proteins of IκB- p100 and p105. 
They contain five to seven C-terminal ankyrin 
repeats which bind to of NF-κB dimerization 
domain and prevent nuclear translocation and 
maintain NF-κB in an inactive state. NF-κB 
activation is mediated by phosphorylation of 
IκB through the IκB kinases that allow Rel 
heterodimers to translocate into the nucleus to 
activate NF-kB dependent genes [32].  
There are two pathways for NF-κB 
activation: 1) classical or canonical, and 2) 
alternative or non-canonical. The classical 
signaling pathway is primarily involved in the 
activation of NF-κB transcription factor in 
response to inflammatory mediator stimuli. 
This is followed by phosphorylation of IKB 
kinase-β (IKK ) to IkBα, leading to its 
ubiquitination and degradation, and thus 
allowing NF-kB to translocate into the 
nucleus. 
In alternative signaling pathway specific 
activation of p52: RelB heterodimers results 
into NF-kB activation under the control of 
NF-kB-inducing kinase (NIK) in response to 
various stimuli. NIK has been shown to 
activate IKK-1, leading to inducible 
processing of p100 with preferential nuclear 
translocation of p52-RelB dimmers [33-34]. 
The IκB kinase (IKK) complex is mainly 
involved in regulation of cell stimulation. It 
consists of two catalytic domains (IKK-α and 
IKK- ) along with a regulatory subunit 
(IKK-/NEMO) [35]. After activation, 
NF-κB-bound IκB proteins are phosphorylated, 
by the activated IκB kinase, and are then 
targeted for poly-ubiquitination and rapid 
degradation through the 26S proteasome 
pathways by creating a binding site for the 
SCF TrCP ubiquitin ligase complex [36]. 
Activated NF-κB allows generation of p50 and 
p52 by the partial processing of p100 and p105, 
and eventually results in the formation of 
dimers which are translocated into the nucleus. 
In nucleus they are involved in transcriptional 
activation of several target genes such as 
MuRF1 [7, 21], MMP9 [22, 37], MyoD cyclin 
[16,17,19], and several inflammatory 
cytokines (Figure 1) [6,8,23]. Besides, NF-κB 
transcription factor is involved in the 
modulation of transactivation of several genes 
by the posttranslational modifications of p65 
(by phosphorylation, acetylation, and 
ubiquitination). This suggests that NF-κB 
serves as a crucial transcription factor with 
multiple levels of regulation, mediating a 
battery of biological functions.  
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Figure 1 Role of NF-kB in loss of skeletal muscle mass in cancer cathexia. NF-kB signaling pathways in skeletal muscle atrophy 
due to cancer cachexia. Step 1: Cancer cachexia is mediated by various stimuli i.e. TNF- α , PIF, Ang-II, IL-6,TRAF6, as well as 
several tumor derived endogenous factors and their interactions with skeletal muscle cells. These interactions at the membrane 
side of the muscle receptors activate IKK complex through MEKK pathway (step 2a)/or by NIK pathway (step 3a). MEKK 
pathway mediated activation of IKK complex results in the activation of NF-kB complex by ubiquitination and degradation of 
IкBα in cytoplasm (step 2b). In NIK pathway, activation of NF-kB complex takes place by the processing of p100, which results 
in the formation of p52-RelB dimmer in cytoplasm (step 3b). Consequently, activated dimmer of NF-kB (p50-RelA or 
p52-RelB) is translocated into nucleus where it regulates muscle wasting through the increased expression of Atrogin-1, MURF1, 
MAFbx, Ube2e2, Myostatin, MMP-9 or decreased expression of MyoD protein causing lowered muscle regeneration and 
increase in degradation of muscle protein through the ubiquitin proteasome dependent mechanism as shown in step 4 and finally 
cancer cachexia.  
 
Role of NF-B in muscle loss due to 
cancer cachexia 
Muscle atrophy is a characteristic feature of 
cancer cachexia, and the degree of muscle loss 
has been correlated with the reduced survival 
rate of cancer patients. Recent literature has 
demonstrated that skeletal muscle loss is 
caused by different mediator based 
mechanisms [4, 6, 8, 10, 23, 25, 38].  
Alterations in muscle protein synthesis and 
degradation arise from the presence of 
tumor-derived factors, such as 
proteolysis-inducing factor (PIF), IL-6, or 
increased production of several endogenous 
factors, such as cytokines or Ang II   [4, 5, 
23]. PIF is a molecule which has a role in 
tumor and mediates cancer cachexia. Earlier 
data in cancer cachexia showed that decrease 
in muscle mass is regulated by PIF and tumor 
produced sulphated glycoproteins which are 
responsible for increased protein degradation 
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and protein synthesis inhibition [39]. 
Furthermore, same investigators have 
confirmed that protein degradation in muscle 
mass is due to enhanced expression of 
components involved in ubiquitin-proteasome 
pathway. Another observation in murine 
myotubes shows that induction of proteosome 
by PIF results in increased DNA binding 
activity of NF-κB, and decreased IkBα 
concentration in cytoplasm [40]. Similarly, a 
study by Smith et al. (2004) on skeletal muscle 
cells showed that NF-κB transcriptional factor 
is involved in the intracellular action of PIF 
for protein degradation by the induction of 
proteasome dependent pathway [41]. Some 
other investigators have also demonstrated that 
activation of PKC is an important signaling 
event in the induction of proteasome 
expression by both PIF and Ang II through the 
phosphorylation and degradation of IkBα and 
subsequent activation of NF-κB [40-42]. A 
relationship between the down regulation of 
protein synthesis and the increased 
degradation of the muscle protein in skeletal 
muscle cells has been established through PIF 
and Ang II mediated induction of the 
ubiquitin-proteasome pathway via activation 
of NF-κB [43]. Same group further established 
that PIF and Ang II are responsible for 
degradation of IkBα and nuclear accumulation 
of NF-κB in myotubes of muscle cells 
transfected with pcDNA3 (-) and wild-type 
PKR but not in the mutant PKRαΔ6. The 
results suggested that PKR phosphorylation is 
responsible for enhancement of protein 
degradation by increased phosphorylation and 
degradation of IkBα through the activation of 
upstream kinase IKK [44]. Increased 
phosphorylation of PKR and eIF 2 in 
gastrocnemius muscle of weight loosing mice, 
bearing the MAC16 tumor (cachectic mice 
bearing murine adenocarcinoma cells), 
suggested that similar processes may occur in 
cancer cachexia [44]. Lewis lung carcinoma 
(LLC) cells are used to create a model for 
cancer cachexia-induced muscle wasting in 
mice. Cai et al. (2004) study showed that 
subcutaneous injection of LLC cells leads to 
the growth of large tumors at the injection 
sites and diffuse tumors in the lungs. Same 
group also observed enhanced activity of 
NF-kB (6-fold) in the muscles of wt mice 
(sham and denervated mice) with tumors 
however no effect on MISR (denervated) mice 
with similar tumor burdens [7]. Increased 
NF-kB activity was presumably due to the 
effects of circulating “cachexia” factors. 
However, when cancer cachexia bearing mice 
were treated with selective NF-kB inhibitor, 
decreased muscle wasting and prolonged 
survival rate were observed. Same group also 
confirmed that activation of NF-kB in MIKK 
mice results in higher expression of the E3 
ubiquitin ligase, and MuRF1 [7]. Another 
study by Kawamura et al. (1999) demonstrated 
that when double stranded 
oligodeoxynucleotides were injected into the 
tumors of C-26 in mice, an attenuation of the 
loss of body weight, gastrocnemius muscle 
mass, and epididymal fat mass were observed 
[45].  
The pro-inflammatory cytokines such as 
TNF-α, interleukin-6 and IL-1 play significant 
role in the pathogenesis of muscle wasting in 
cachexia [23]. Adler et al. (1999) have 
demonstrated that increased production of IL-6 
is primarily regulated by NF-kB mediated 
transcription factor in cachexia of prostate 
cancer [46].  Some studies have suggested 
that NF-kB inhibition may result in 
amelioration of cancer cachexia in mouse 
tumor model [47] as well as in cultured human 
leukemia Jurkat cells in mice [48]. Recently, a 
significant association between IL-6 and 
cachexia in patients with prostate cancer as 
well as in JCA-1 tumor bearing mice has been 
established [49]. Furthermore, these authors 
demonstrated that by inhibiting NF-κB 
activation in the JCA-1 tumor bearing mice, 
prostate cancer induced development of 
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cachexia was significantly attenuated through 
the down regulation of IL-6 production. 
Similarly, a recent study by Nai et al. (2007) 
on cachexia in colon 26 tumor-bearing mice 
(Cachexia was induced by subcutaneous 
grafting of colon carcinoma C26 cells in the 
dorsal region of 7-week-old mice) had 
suggested that NF-κB inhibitor attenuated the 
development of cachexia through the 
inhibition of IL-6 expression, and by 
inhibition of activation of the NF-κB 
transcription factor in tumor tissues [50]. An 
earlier study showed that interleukin-6 (IL-6) 
is involved in muscle wasting through the 
lysosomal (cathepsin) and non-lysosomal 
(proteasome) mediated pathways in tumor 
bearing animals [51].  However, recently a 
report on mouse bearing colon 26 
adenocarcinoma in experimental cancer 
cachexia, demonstrated enhanced 
concentration of TNF-alpha and IL-6 in spleen 
of tumor-bearing animals in comparison to 
control, which is mediated by the activation of 
NF-κB transcription factors. Furthermore 
authors suggest that low dose of indomethacin 
alleviates the cachexia and prevents body 
weight loss in muscle atrophy by decreasing 
the activation of NF-κB transcription factor as 
well as lowering the serum levels of 
TNF-alpha and IL-6 [52].  Some studies have 
demonstrated that TNF-alpha has catabolic 
effect on energy storage body such as skeletal 
muscle and adipose tissue [53].  TNF-alpha 
produces reactive oxygen species that cause 
increased expression and activation of the 
NF-kB transcription factor, which in turn 
results into skeletal muscle atrophy by 
decreased protein synthesis, and increased 
protein degradation through ubiquitin– 
proteasome mediated pathway [54-55].  
Earlier published report by Ladner et al. 
(2003) indicates that TNF-alpha 
induces NF-κB activation in a biphasic manner. 
First, transient phase is terminated within 1 h 
of cytokine addition. Second phase persists for 
an additional 24-36 h. The transient phase is 
mediated by the degradation and consequent 
re-synthesis of IkB alpha. Second phase 
activity correlated with down-regulation of 
both IkBα and IkBβ proteins. Authors further 
demonstrated that cytokines involved in 
activation of NF-κB transcription factor and 
protein degradation are mediated by IKK/26 S 
proteasome pathway dependent mechanism in 
skeletal muscles associated with cachexia [56]. 
Another in-vitro study confirmed 
that TNF-induced activation of NF-κB is 
responsible for inhibition of 
skeletal muscle differentiation by the 
decreased expression of MyoD mRNA. 
However in mouse muscle, both TNF alpha 
and IFNγ signaling were required for the 
NF-κB-dependent down-regulation of MyoD 
and dysfunction of skeletal myofibers [17]. 
Tumor necrosis factor alpha and gamma 
interferon also induce muscle degeneration by 
activating the transcription factor NF-κB by 
the nitric oxide (NO) production which 
stimulates MyoD mRNA loss. Furthermore, 
cytokine treatment of iNOS(-/-) mice, 
activated NF-κB and did not trigger MyoD 
mRNA degeneration, demonstrating that 
NF-κB-mediated muscle wasting requires an 
active iNOS-NO pathway [19]. This suggests 
that iNOS may play an important role in 
cytokine-induced cachexia, and may act as 
potential therapeutic target for cancer cachexia. 
A recent study by Bera  and Ray (2009) 
demonstrated that TNF-alpha involved in 
degradation of MyoD and myogenin mRNA, 
which may lead to severe muscle wasting 
and cachexia in carcinogen-induced sarcoma 
of mouse muscle. These authors further 
suggested that the activation of TNF-alpha 
mediated nitric oxide production pathway is 
involved in degradation of MyoD and 
myogenin mRNA by activation of NFkappaB 
transcription factor [57]. Matrix 
metalloproteinases (MMPs) are a family of 
proteinases that can degrade proteins involved 
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in intracellular and extracellular remodeling. 
Recent in-vivo and in-vitro study by us [22] 
and another group [58] has suggested that 
TWEAK (Tumor necrosis factor-like weak 
inducer of apoptosis) and TNF-α play a major 
role in skeletal muscle loss by production of 
metalloproteinase-9 (MMP-9). We further 
demonstrated that when dominant-negative 
inhibitor of NF-κB (IκBαΔN) was transected 
in muscle cells, expression of MMP9 was 
completely blocked in myotubes; thus 
confirming that NF-κB plays a major role in 
the production of MMP-9 in skeletal muscle 
cells. 
A recent study on Lewis lung carcinoma 
(LLC) model of induced cancer cachexia 
showed that TRAF6 (TNF receptor associated 
factor) plays a major role in cancer cachexia 
along with simultaneous loss of muscle mass 
[59]. Authors further showed that when 
TRAF6 mko and TRAF6 f/f were injected in 
LLC cell in left flank of mice, significant 
reduction in fiber cross-sectional area was 
observed in skeletal muscle of TRAF6 f/f mice. 
However, in LLC- bearing TRAF6mko mice, 
fiber cross-sectional area was completely 
preserved.  LLC-bearing TRAF6mko mice 
showed significant inhibition of activity of 
NF-κB in skeletal muscle as compared to 
TRAF6f/f mice. Furthermore, authors 
confirmed that LLC injected TRAF6mko mice 
had complete inhibition of expression of 
MuRF1, LC3B, and Beclin1 in comparison to 
TRAF6f/f mice and suggested that inhibitor of 
TRAF6 may play major role in prevention of 
tumor-induced activation of 
ubiquitin–proteasome systems in skeletal 
muscle cells [59]. 
Rhoads et al. (2010)
 
investigated
 
the 
expression of nuclear levels of p50, p65, Bcl-3, 
phospho-p65 (Ser536), and IκBα in human 
skeletal muscle of 14 gastric cancer patients 
(similar to animal models of cancer cachexia) 
and 10 healthy controls [9]. The study showed 
that there was no change in nuclear levels of 
p50, Bcl-3, and p65 in controls and patients; 
however, a significant (25%) increased 
expression in phospho-p65, and 25% 
decreased expression of IκBα were observed in 
skeletal muscle of patients as compared to 
controls. Moreover, no correlation between the 
stage of cancer and extent of decrease in IkB 
alpha was observed, suggesting that activation 
of NF-kB is an early and sustained event in 
humans with gastric cancer [9].  
NF-kB mediated therapeutic targets 
to inhibit muscle atrophy in cancer 
cachexia 
Cachexia therapy for last one decade is 
mainly based on skeletal muscle target 
molecules which are able to stimulate the 
anabolic pathways and have ability to reduce 
catabolic processes. Recent evidence 
demonstrates the relationship between the 
depression of protein synthesis in skeletal 
muscle by different mediators, and the 
enhanced degradation of the myofibrillar 
protein myosin through activation of NF-kB, 
resulting in an increased expression and 
activity of the ubiquitin-proteasome 
proteolytic pathway in cancer cachexia 
[3,4,6,10]. These studies imply that the 
molecules which interfere with activation of 
NF-kB may be effective in the treatment of 
skeletal muscle atrophy in cancer cachexia. 
Hence, we summarize the effect of important 
molecules which possibly play significant role 
in inhibition of NF-κB transcription factor and 
can be useful in treatment of cancer cachexia. 
Eicosapentaenoic acid (EPA): EPA is a 
polyunsaturated fatty acid with antitumor and 
anticachectic effects. Recent studies have 
shown that in cachexia, EPA may attenuate 
protein degradation, by preventing NF-kB 
accumulation in the nucleus [24, 26]. A study 
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using murine MAC16 cachexia model has 
shown that it preserves muscle mass by down 
regulation of increased expression of the 
ubiquitin–proteasome pathway [60], and 
prevented PIF-induced nuclear migration of 
NF-kB by stabilizing the IkB/NF-kB complex 
through inhibition of upstream signaling 
pathways [40]. Similar opinions have been 
advanced to substantiate that EPA may block 
the action of PIF-induced nuclear migration of 
NF-kB and attenuates the development of 
cachexia in pancreatic cancer patients [61-62]. 
Resveratrol: It is a natural phytoalexin 
commonly found in red wine. It is an inhibitor 
of NF-kB activation and acts through 
inhibition of IKK dependent NF-kB activation 
[63]. It has ability to inhibit PIF-induced 
proteasome expression and acts as 
anticachectic agent in mice bearing the 
MAC16 tumour, which induces profound 
cachexia involving wasting of skeletal muscle 
[64].  Wyke et al (2004) demonstrated that 
resveratrol (1 mg/ kg body weight) 
significantly attenuated the PIF-induced 
expression of the ubiquitin-proteasome 
proteolytic pathway, and decreased muscle 
protein degradation and loss of body weight by 
the lowering of NF-kappaB DNA-binding 
activity in mice bearing the MAC16 tumor 
[65]. A previous study has shown that 
resveratrol inhibits  loss of 
skeletal muscle mass, induced by C26 
adenocarcinoma tumors through its inhibition 
of NF-κB (p65) activity in skeletal muscle and 
suggest that use of oral resveratrol therapy 
may protect from cancer-induced atrophy 
through the inhibition of NF-κB and increases 
the gain of skeletal muscle mass [66].  
Epigallocatechin-3-gallate (EGCG): EGCG 
is a polyphenolic component in green tea.  It 
acts as a potent preventive agent 
against cancer induced cachexia. EGCG 
counteracts cachexia-provoked muscle wasting 
by regulating the expressions of NF-κB as well 
as downstream mediators, MuRF1 and MAFbx. 
Wang et al. (2011) have suggested that EGCG 
may be a potential molecule in therapeutics of 
the tumor-induced muscle atrophy [67].  
Beta-hydroxy-beta-methylbutyrate (HMB): 
HMB is an anticatabolic agent. Earlier reports 
illustrated that HMB attenuates PIF-induced 
protein degradation in muscle cells, by 
decreased expression of the 
ubiquitin-proteasome pathway enzymes [25, 
68]. Furthermore, HMB is involved in 
prevention of NF-kB activation through 
decreased expression of PKC, resulting in 
IkB/NF-kB complex stabilization in murine 
model of cachexia [69].  Recently it has been 
found that beta-hydroxy-beta-methylbutyrate 
supplementation in tumor-bearing rats induced 
a lower tumor weight and tumor cell 
proliferation; and more than 100% reduction in 
tumor cell proliferation was accompanied by 
the increased expression of IkB-alpha [70]. 
Further, this study observed 17% suppression 
of NF-kappaB p65 subunit content by the 
HMB supplementation. This suggests that 
HMB supplementation may increase 
skeletal muscle mass in tumor-bearing rats by 
inhibiting the NF-kappaB activation.  A study 
in placebo-controlled clinical trial of  HMB 
in patients with cancer cachexia showed that 
using L-glutamine, L-arginine together with 
HMB in advanced cancer patients, results in 
increased body weight and  an increase in 
lean body mass; however, no changes were 
observed in fat mass [71]. 
Pyrrolidine dithiocarbamate (PDTC): PDTC 
is an inhibitor of NFkappaB. A recent study on 
cachexia in colon 26 tumor-bearing mice 
suggested that it attenuates the development 
of cachexia in colon 26 tumor-bearing mice 
through the inhibition of IL-6 expression [72]. 
Furthermore, this compound also inhibited the 
wasting of gastrocnemius muscle, carcass 
weight and epididymal fat mass of tumor 
tissues by the diminishing of the NF-kB 
activation. 
Dehydroxymethylepoxyquinomicin 
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(DHMEQ): DHMEQ shows anti–NF-kB 
activity in cultured human leukemia Jurkat 
cells [48]. A previous study by Kuroda et al. 
(2005) demonstrated a significant association 
between IL-6 and cachexia in patients with 
prostate cancer as well as in JCA-1 tumor 
bearing mice [49]. Furthermore, same group 
had established that NF-kB inhibitor DHMEQ 
has ability to prevent cachexia induced by 
prostate cancer through the inhibition of IL-6 
production in a JCA-1 tumor bearing mice. 
Indomethacin (IND): Zhou et al. (2003) 
investigated the role of IND by categorizing 
their experiment into five groups: (a) control, 
(b) tumor-bearing plus saline, (c) 
tumor-bearing plus IND (0.25 mg x kg(-1)), 
(d) tumor-bearing plus IND (0.5 mg x kg(-1)), 
and (e) tumor-bearing plus IND (2 mg x kg(-1). 
Then colon 26 adenocarcinoma cells of murine 
were inoculated subcutaneously to induce 
cachexia. Saline and IND were given 
intraperitoneally from the onset of cachexia 
upto seven days and thereafter serum levels of 
TNF-alpha, IL-6, and activity of NF-kappaB in 
the spleen of male BABL/c mice were 
observed [52]. The study demonstrated 
enhanced concentration of TNF-alpha and IL-6 
in spleen of tumor-bearing animals as 
compared to control, which is mediated by the 
activation of NF-kB transcription factors. 
Furthermore, authors suggested that low dose 
of indomethacin (0.5 mg·kg-1) alleviated the 
cachexia, and prevented body weight loss in 
muscle atrophy by decreased activation of 
NF-kB and lowering the levels of TNF-alpha 
plus IL-6 expression [52].  
Ghrelin: Earlier animal studies in mice, 
inoculated with human melanoma cells of 
cancer-cachexia demonstrated that Ghrelin 
treatment might attenuate cachexia by 
stimulation of food intake and gain in body 
weight loss [72-74]. Another study confirmed 
that tumor implanted rats treated with either 
Ghrelin or the Ghrelin analog BIM-28131 
demonstrated improvement in food intake and 
gain of body weight [75]. Recent literature is 
suggestive of increased Ghrelin secretion from 
tumor tissues might be counteracting skeletal 
muscle mass wasting by stimulation of food 
intake and activation of anabolic pathways by 
the inhibition of NF-kB activation [76].   
Curcumin: Curcumin is a natural product 
from turmeric which is believed to prevent 
activation of NF-kB by blocking 
phosphorylation and subsequent degradation 
of IkB-alpha. It has been shown to increase the 
rate and extent of muscle regeneration after 
trauma [77]. Wyke et al.(2004) study in murine 
myotube of mice bearing the MAC16 tumor 
suggested that PIF-induced expression of 
ubiquitin-proteasome components mediated 
protein degradation were completely 
attenuated by low dose of curcumin (50 
microM);  however, higher dose of curcumin 
(150 and 300 mg kg(-1) had no effect [65].  
Thalidomide: It is reported to reduce the 
levels of TNFα, by enhancing the rate of 
degradation of TNF-alpha mRNA. This also 
reduces skeletal muscle wasting in cancer 
patients by blocking of the NF-kB-regulated 
genes through suppression of IKK activity [78]. 
Previous study in patients of  esophageal 
cancer  have shown that  when patients 
received an isocaloric diet only, for 2 weeks, 
had lost both body weight and lean body mass; 
however, reverse was observed in the patients 
who received thalidomide [79]. Another study 
in patients with advanced pancreatic cancer 
confirmed that patients with placebo group had 
lost approximately 10% of their body weight 
while those who received thalidomide had 
stabilized arm muscle mass and did not lose 
their body weight [80]. Recent published data 
also suggests that thalidomide may attenuate 
the signaling cascade of ANG II, PIF, or 
TNF-alpha, and down regulate the increased 
expression of the ubiquitin-proteasome 
dependent pathway by inhibition of NF-kB 
activation [6]. 
Double-stranded oligodeoxynucleotides: 
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Double-stranded oligodeoxynucleotides 
(ODN) transfection strategy is based on the 
principle that 'decoy' cis-elements are 
responsible for blocking of binding of nuclear 
transcription factors to promoter regions of 
targeted genes, and influencing the inhibition 
of gene transactivation. Previous study in 
tumors of adenocarcinoma colon26 mice had 
shown that targeting of NF-kappa B (NF kappa 
B) binding cis-elements with the transfection 
of synthetic double-stranded 
oligodeoxynucleotides decoy resulted in 
attenuation of the reduction in body weight, 
epididymal fat, gastrocnemius muscle mass 
that was induced by the presence of tumor [45]. 
Moreover, authors suggested 
that adenocarcinoma colon26 induced 
cachexia could be inhibited by the blocking 
of NF kappa B activation by the application of 
molecular decoy strategy.  Recent studies 
demonstrated that inhibitor of double stranded 
RNA-dependent protein kinase (PKR) play 
major role in attenuation of  NF-kB 
activation  as well as in expression of the 20S 
proteasome in weight loosing mice bearing the 
MAC16 tumor [43,44,81]. Furthermore these 
authors suggested that inhibitor of PKR may 
be useful therapeutic target against the tumor 
showing higher expression of PKR and 
increased NF-kB activation. 
NBD peptide: NBD peptide is a competitive 
inhibitor of the IKK complex. It is reported to 
have therapeutic potential to ameliorate 
tumor-induced muscle wasting.  Recently, a 
study by Wysong et al. (2011) have shown that 
when tumor bearing mice were treated with 
NBD peptide (80, 200, 500 microgram), a dose 
dependent increase in lean body mass, and fat 
mass was recorded as compared to non treated 
tumor bearing mice [81]. Furthermore it was 
demonstrated that tumor bearing mice had 
significant hind limb atrophy as compared to 
non-tumor bearing mice. However, in NBD 
peptide (200, 500 microgram) treated mice, 
complete reversal of hind limb wasting and 
reduction of size of tumor volume were 
observed as compared to untreated mice. 
Moreover, they further demonstrated that NBD 
untreated mice had increased NF-kB activity 
(increased phospho-p65 but no change in p65) 
in cachextic gastrocnemius muscle, which was 
reversed with NF-kB inhibition by treatment 
with NBD peptide. Same group also confirmed 
that NBD treated tumor-challenged mice 
showed decreased expression of MuRF1, and 
MAFbx/ Atrogin-1 genes as compared to non 
tumor bearing controls mice, suggesting that 
inhibition of NF-κB by the NBD peptide is 
involved in inhibition of skeletal muscle 
atrophy through the decreased expression of 
enzymes involved in ubiquitin pathways [82]. 
Conclusion and Future Prospective 
Cancer cachexia is a type of cancer metabolic 
syndrome characterized by irreversible erosion 
of body cell mass, progressive weakness and 
muscle atrophy in response to malignant 
growth.  The mechanism of development of 
cachexia has remained illusive so far but two 
widely accepted theories include the 
deregulation of leptin feedback loop control 
and the proteolysis-inducing and lipid 
mobilising factors (PIF and LMF)
 
[1,4,6]. 
Whereas the pathologic deregulation of leptin 
loop control is implicated in altering the 
neuropeptidergic control cycles leading to 
decreased energy intake but high metabolic 
demand for nutrients, the PIF and LMF which 
are present in the urine of cachectic patients 
are closely related to weight loss in cachexia. 
LMF produces a significant increase in 
mitochondrial uncoupling proteins (UCPs) 1, 2, 
and 3 which are involved in the control of 
energy metabolism through thermogenesis in 
brown adipose tissue as well as in skeletal 
muscles and liver
5
. Another view elucidating 
the mechanism of cancer cachexia is based 
upon induction by proinflammatory cytokines. 
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Chronic systemic inflammatory response and 
the acute phase proteins are elevated as 
evident from high serum levels of IL-1, IL-6 
and TNF in cancer patients [4, 6, 7, 10]. These 
cytokines also stimulate expression of leptin 
and influence satiety resulting in long-term 
inhibition of food intake.   
With recent accumulating evidence, 
mediator based myriad of signaling pathways 
such as ubiquitin-proteasome and NF-kB 
signaling pathways are suggested to be the part 
of the mechanisms by which cancer induces 
adipose tissue and skeletal muscle loss. Upon 
interaction with their unique receptors on 
skeletal muscle, these mediators activate 
NF-kappaB transcription factor which is 
essential for atrophy related degradation of 
muscle proteins to occur. The mechanisms by 
which NF-kB promotes muscle wasting in 
cancer cachexia remain poorly understood but 
this could be possibly due to its ability to 
inhibit myogenesis [4, 27,38,43] or to induce 
protein turnover through the ubiquitin 
proteasome pathway [3, 6,7, 11, 25, 44, 65]. 
Previous studies related to discovery that 
NF-kB activation is sufficient to cause skeletal 
muscle atrophy and that blockade of the 
NF-kB pathway can ameliorate skeletal muscle 
atrophy are suggestive of a new set of drug 
targets for clinical intervention in cancer 
cachexia. Recently various therapeutic NF-kB 
blockers such as Resveratrol, 
Epigallocatechin-3-gallate, 
Beta-hydroxy-beta-methylbutyrate, 
Dehydroepiandrosterone, Eicosapentaenoic 
acid-enriched oral supplements, Pyrrolidine 
dithiocarbamate, 
Dehydroxymethylepoxyquinomicin, 
Indomethacin, NBD peptide, indomethacin, 
Ghrelin, Thalidomide  have been identified 
which are effective in treatment of  cancer 
cachexia [6, 24,49, 50, 66, 67,70,76,81, 82]. 
Although the mechanisms of action of these 
drugs in prevention of cancer cachexia is not 
well understood; but many of these drugs have 
been shown to attenuate cancer cachexia by 
inhibition of NF-κB activation in various cell 
types. This is particularly significant, as of 
now there are no drugs approved for the 
treatment of skeletal muscle atrophy in cancer 
cachexia that could demonstrate significant 
improvement in treatment outcome, functional 
status and quality of life. Therefore, future 
studies should be directed towards better 
defining the mechanism involved to inhibit 
cancer cachexia by NF-kB blockade and 
determining the potential of these therapeutic 
agents through potential clinical trials in 
animal models and in human cancer cachexia 
patients. 
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